U.S. markets open in 2 hours 25 minutes

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.7800-0.0400 (-1.05%)
At close: 4:00PM EDT
4.0800 +0.30 (7.94%)
Pre-Market: 07:04AM EDT

NeuroBo Pharmaceuticals, Inc.

200 Berkeley Street
Office 19th Floor
Boston, MA 02116
United States
857 702 9600
http://www.neurobopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeong Gu Kang Ph.D.Pres, CEO, Sec., Interim CFO, Treasurer & Director427.31kN/A1972
Mr. Akash BakshiSr. VP & COON/AN/A1989
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

Corporate Governance

NeuroBo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.